TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Frequent Hemodialysis Network: Daily Trial
Brief Summary: The Frequent Hemodialysis Network (FHN) Daily Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialysis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale.


Options:
A: Arm Label: Standard; Type: NO_INTERVENTION; Interventions: Device: Standard Hemodialysis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: with Blood Volume Management (BVM®) only | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring | Intervention Type: DEVICE; Name: Standard Hemodialysis; Assigned to Arm(s): Standard | Intervention Type: DEVICE; Name: with Blood Volume Management (BVM®) only; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nocturnal home hemodialysis | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nocturnal home hemodialysis | Intervention Type: BEHAVIORAL; Name: Nocturnal home hemodialysis; Assigned to Arm(s): 1, 2
C: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
D: Arm Label: Subjects undergoing sodium alignment; Type: N/A; Interventions: Other: Dialysate and serum sodium concentration aligned | Arm Label: Subjects not undergoing sodium alignment; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: Dialysate and serum sodium concentration aligned; Assigned to Arm(s): Subjects undergoing sodium alignment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
Brief Summary: The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.


Options:
A: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) | Arm Label: Methylphenidate (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) - Placebo | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH); Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH) - Placebo; Assigned to Arm(s): Methylphenidate (Placebo)
B: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: ADHD; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
Brief Summary: The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
B: Arm Label: OROS-Methylphenidate and placebo for inattentive type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for inattentive type pts | Arm Label: OROS-Methylphenidate and placebo for combined type pts; Type: OTHER; Interventions: Drug: OROS-Methylphenidate and placebo for combined type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for inattentive type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for inattentive type pts | Intervention Type: DRUG; Name: OROS-Methylphenidate and placebo for combined type pts; Assigned to Arm(s): OROS-Methylphenidate and placebo for combined type pts
C: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) | Arm Label: Methylphenidate (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) - Placebo | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH); Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH) - Placebo; Assigned to Arm(s): Methylphenidate (Placebo)
D: Arm Label: Midazolam; Type: EXPERIMENTAL; Interventions: Drug: Midazolam | Arm Label: Isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic saline | Arm Label: Fentanyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Fentanyl | Intervention Type: DRUG; Name: Isotonic saline; Assigned to Arm(s): Isotonic saline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy
Brief Summary: Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.


Options:
A: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
B: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Mepolizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab 100 mg | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab 100 mg
D: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy
Brief Summary: Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.


Options:
A: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
B: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
C: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy
Brief Summary: Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.


Options:
A: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo
B: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
C: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
D: Arm Label: Alair; Type: EXPERIMENTAL; Interventions: Device: Alair System | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Alair System | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Alair | Intervention Type: DEVICE; Name: Alair System; Assigned to Arm(s): Sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial
Brief Summary: A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physical activity levels, b) will have a higher health-related quality of life at measurement dates and, c) will have greater improvements in psychosocial predictors.


Options:
A: Arm Label: PATHway; Type: EXPERIMENTAL; Interventions: Behavioral: PATHway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PATHway; Assigned to Arm(s): PATHway
B: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
C: Arm Label: Center-based cardiac rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Center-based cardiac rehabilitation | Arm Label: Home-based training with telemonitoring guidance; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based training with telemonitoring guidance | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Center-based cardiac rehabilitation; Assigned to Arm(s): Center-based cardiac rehabilitation | Intervention Type: BEHAVIORAL; Name: Home-based training with telemonitoring guidance; Assigned to Arm(s): Home-based training with telemonitoring guidance
D: Arm Label: Medication text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for medication adherence | Arm Label: Exercise text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for exercise regimen | Arm Label: Usual care, medication adherence; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care, exercise regimen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text message reminder for medication adherence; Assigned to Arm(s): Medication text message | Intervention Type: BEHAVIORAL; Name: Text message reminder for exercise regimen; Assigned to Arm(s): Exercise text message

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial
Brief Summary: A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physical activity levels, b) will have a higher health-related quality of life at measurement dates and, c) will have greater improvements in psychosocial predictors.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Do CHANGE | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Do CHANGE; Assigned to Arm(s): Intervention
B: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
C: Arm Label: AB sequence; Type: EXPERIMENTAL; Interventions: Other: Usual care followed by the use of HeartHab application | Arm Label: BA sequence; Type: EXPERIMENTAL; Interventions: Other: Use of HeartHab application followed by usual care | Intervention Type: OTHER; Name: Use of HeartHab application followed by usual care; Assigned to Arm(s): BA sequence | Intervention Type: OTHER; Name: Usual care followed by the use of HeartHab application; Assigned to Arm(s): AB sequence
D: Arm Label: The Box; Type: EXPERIMENTAL; Interventions: Other: The Box | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: The Box; Assigned to Arm(s): The Box

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial
Brief Summary: A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physical activity levels, b) will have a higher health-related quality of life at measurement dates and, c) will have greater improvements in psychosocial predictors.


Options:
A: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A
B: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic Information | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based lifestyle counseling messages | Intervention Type: BEHAVIORAL; Name: Web-based lifestyle counseling messages; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Generic Information; Assigned to Arm(s): 1
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group I; Type: EXPERIMENTAL; Interventions: Behavioral: self-regulation | Intervention Type: BEHAVIORAL; Name: self-regulation; Assigned to Arm(s): Intervention Group I

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial
Brief Summary: A randomized control trial (RCT) is planned to evaluate a web-based intervention (CardioFit) against usual care in increasing physical activity levels in patients with Coronary Artery Disease (CAD). We hypothesize that compared to usual care, participants in CardioFit will; a) have increased physical activity levels, b) will have a higher health-related quality of life at measurement dates and, c) will have greater improvements in psychosocial predictors.


Options:
A: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training
B: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prehab Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Prehab Intervention | Intervention Type: BEHAVIORAL; Name: Prehab Intervention; Assigned to Arm(s): Prehab Intervention

Answer: B